Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research

EMBARC/BRR definitions working group

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

There is a need for a clear definition of exacerbations used in clinical trials in patients with bronchiectasis. An expert conference was convened to develop a consensus definition of an exacerbation for use in clinical research.A systematic review of exacerbation definitions used in clinical trials from January 2000 until December 2015 and involving adults with bronchiectasis was conducted. A Delphi process followed by a round-table meeting involving bronchiectasis experts was organised to reach a consensus definition. These experts came from Europe (representing the European Multicentre Bronchiectasis Research Collaboration), North America (representing the US Bronchiectasis Research Registry/COPD Foundation), Australasia and South Africa.The definition was unanimously approved by the working group as: a person with bronchiectasis with a deterioration in three or more of the following key symptoms for at least 48 h: cough; sputum volume and/or consistency; sputum purulence; breathlessness and/or exercise tolerance; fatigue and/or malaise; haemoptysis AND a clinician determines that a change in bronchiectasis treatment is required.The working group proposes the use of this consensus-based definition for bronchiectasis exacerbation in future clinical research involving adults with bronchiectasis.

Original languageEnglish (US)
JournalThe European respiratory journal
Volume49
Issue number6
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Fingerprint

Bronchiectasis
Lung
Research
Sputum
Clinical Trials
Australasia
Exercise Tolerance
Hemoptysis
North America
South Africa
Cough
Dyspnea
Chronic Obstructive Pulmonary Disease
Fatigue
Registries

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Pulmonary exacerbation in adults with bronchiectasis : a consensus definition for clinical research. / EMBARC/BRR definitions working group.

In: The European respiratory journal, Vol. 49, No. 6, 01.06.2017.

Research output: Contribution to journalArticle

@article{d01bf6ea4ecd4684a4f975d9e2b6568d,
title = "Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research",
abstract = "There is a need for a clear definition of exacerbations used in clinical trials in patients with bronchiectasis. An expert conference was convened to develop a consensus definition of an exacerbation for use in clinical research.A systematic review of exacerbation definitions used in clinical trials from January 2000 until December 2015 and involving adults with bronchiectasis was conducted. A Delphi process followed by a round-table meeting involving bronchiectasis experts was organised to reach a consensus definition. These experts came from Europe (representing the European Multicentre Bronchiectasis Research Collaboration), North America (representing the US Bronchiectasis Research Registry/COPD Foundation), Australasia and South Africa.The definition was unanimously approved by the working group as: a person with bronchiectasis with a deterioration in three or more of the following key symptoms for at least 48 h: cough; sputum volume and/or consistency; sputum purulence; breathlessness and/or exercise tolerance; fatigue and/or malaise; haemoptysis AND a clinician determines that a change in bronchiectasis treatment is required.The working group proposes the use of this consensus-based definition for bronchiectasis exacerbation in future clinical research involving adults with bronchiectasis.",
author = "{EMBARC/BRR definitions working group} and Hill, {Adam T.} and Haworth, {Charles S.} and Stefano Aliberti and Alan Barker and Francesco Blasi and Wim Boersma and Chalmers, {James D.} and {De Soyza}, Anthony and Katerina Dimakou and Elborn, {J. Stuart} and Charles Feldman and Patrick Flume and Goeminne, {Pieter C.} and Loebinger, {Michael R.} and Rosario Menendez and Lucy Morgan and Marlene Murris and Eva Polverino and Alexandra Quittner and Ringshausen, {Felix C.} and Gregory Tino and Antoni Torres and Montserrat Vendrell and Tobias Welte and Rob Wilson and Conroy Wong and Anne O'Donnell and Timothy Aksamit",
year = "2017",
month = "6",
day = "1",
doi = "10.1183/13993003.00051-2017",
language = "English (US)",
volume = "49",
journal = "European Respiratory Journal, Supplement",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "6",

}

TY - JOUR

T1 - Pulmonary exacerbation in adults with bronchiectasis

T2 - a consensus definition for clinical research

AU - EMBARC/BRR definitions working group

AU - Hill, Adam T.

AU - Haworth, Charles S.

AU - Aliberti, Stefano

AU - Barker, Alan

AU - Blasi, Francesco

AU - Boersma, Wim

AU - Chalmers, James D.

AU - De Soyza, Anthony

AU - Dimakou, Katerina

AU - Elborn, J. Stuart

AU - Feldman, Charles

AU - Flume, Patrick

AU - Goeminne, Pieter C.

AU - Loebinger, Michael R.

AU - Menendez, Rosario

AU - Morgan, Lucy

AU - Murris, Marlene

AU - Polverino, Eva

AU - Quittner, Alexandra

AU - Ringshausen, Felix C.

AU - Tino, Gregory

AU - Torres, Antoni

AU - Vendrell, Montserrat

AU - Welte, Tobias

AU - Wilson, Rob

AU - Wong, Conroy

AU - O'Donnell, Anne

AU - Aksamit, Timothy

PY - 2017/6/1

Y1 - 2017/6/1

N2 - There is a need for a clear definition of exacerbations used in clinical trials in patients with bronchiectasis. An expert conference was convened to develop a consensus definition of an exacerbation for use in clinical research.A systematic review of exacerbation definitions used in clinical trials from January 2000 until December 2015 and involving adults with bronchiectasis was conducted. A Delphi process followed by a round-table meeting involving bronchiectasis experts was organised to reach a consensus definition. These experts came from Europe (representing the European Multicentre Bronchiectasis Research Collaboration), North America (representing the US Bronchiectasis Research Registry/COPD Foundation), Australasia and South Africa.The definition was unanimously approved by the working group as: a person with bronchiectasis with a deterioration in three or more of the following key symptoms for at least 48 h: cough; sputum volume and/or consistency; sputum purulence; breathlessness and/or exercise tolerance; fatigue and/or malaise; haemoptysis AND a clinician determines that a change in bronchiectasis treatment is required.The working group proposes the use of this consensus-based definition for bronchiectasis exacerbation in future clinical research involving adults with bronchiectasis.

AB - There is a need for a clear definition of exacerbations used in clinical trials in patients with bronchiectasis. An expert conference was convened to develop a consensus definition of an exacerbation for use in clinical research.A systematic review of exacerbation definitions used in clinical trials from January 2000 until December 2015 and involving adults with bronchiectasis was conducted. A Delphi process followed by a round-table meeting involving bronchiectasis experts was organised to reach a consensus definition. These experts came from Europe (representing the European Multicentre Bronchiectasis Research Collaboration), North America (representing the US Bronchiectasis Research Registry/COPD Foundation), Australasia and South Africa.The definition was unanimously approved by the working group as: a person with bronchiectasis with a deterioration in three or more of the following key symptoms for at least 48 h: cough; sputum volume and/or consistency; sputum purulence; breathlessness and/or exercise tolerance; fatigue and/or malaise; haemoptysis AND a clinician determines that a change in bronchiectasis treatment is required.The working group proposes the use of this consensus-based definition for bronchiectasis exacerbation in future clinical research involving adults with bronchiectasis.

UR - http://www.scopus.com/inward/record.url?scp=85030033042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030033042&partnerID=8YFLogxK

U2 - 10.1183/13993003.00051-2017

DO - 10.1183/13993003.00051-2017

M3 - Article

C2 - 28596426

AN - SCOPUS:85030033042

VL - 49

JO - European Respiratory Journal, Supplement

JF - European Respiratory Journal, Supplement

SN - 0903-1936

IS - 6

ER -